Estimated costs of managing treatment-related adverse events (TRAEs) of nivolumab (nivo) and docetaxel (doc) in the CheckMate 017 and CheckMate 057 phase III non-small cell lung cancer (NSCLC) trials
| Autor: | Meena Venkatachalam, Guilhem Pietri, Beata Korytowsky, David D. Stenehjem, John R. Penrod |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research Chemotherapy medicine.medical_specialty business.industry medicine.medical_treatment Fda approval Checkmate non-small cell lung cancer (NSCLC) medicine.disease 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Docetaxel 030220 oncology & carcinogenesis Internal medicine medicine Nivolumab Healthcare Cost and Utilization Project Adverse effect business health care economics and organizations medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 34:6617-6617 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 6617Background: Nivo, a PD-1 antibody, received FDA approval based on superior overall survival in metastatic squamous (SQ) and non-squamous (NSQ) NSCLC patients who have progressed on or after platinum-based doublet chemotherapy. The purpose of this study was to assess the frequency and associated costs of grade 2–4 AEs in the CheckMate 017 (SQ) and CheckMate 057 (NSQ) phase III pivotal trials of nivo vs doc in stage IIIB/IV NSCLC. Methods: Patient-level data from these two trials were utilized to estimate the frequency of TRAEs requiring management in the nivo and doc arms, including serious and non-serious TRAEs. Minimum follow-up for AE reporting at database lock was 12 months. Grade 3–4 AE costs by event were identified from Healthcare Cost and Utilization Project (HCUP) data in 2010, which were adjusted to reflect 2012-equivalent US costs. Healthcare utilization associated with grade 2 AEs was based on clinical opinion and costs were based on HCUP or other sources as appropriate. Results: In both tr... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|